A combined DTPa-IPV booster vaccine was administered as a 4th or 5th dose after DTPa or DTPw priming. Over 99% vaccines developed antibody levels considered to be protective to diphtheria, tetanus and poliovirus, and >95% mounted a response to acellular pertussis antigens. Rectal temperature >39.5 degrees C was observed in at most 3.2% of vaccinees. Swelling >50 mm occurred in 24% of DTPa-primed compared to 5.5% of DTPw-primed children. Large swelling involving the entire upper arm (extending to involve the elbow joint) was reported for up to 1.2% of DTPa-primed subjects, which is consistent with literature reports for other DTPa vaccines.

Safety and immunogenicity of a combined DTPa-IPV vaccine administered as a booster from 4 years of age: a review / Jacquet JM; Bégué P; Grimprel E; Reinert P; Sandbu S; Silfverdal SA; Faldella G; Nolan T; Lambert S; Richmond P; Marshall H; Roberton D; Schuerman L.. - In: VACCINE. - ISSN 0264-410X. - STAMPA. - 24(13):(2006), pp. 2440-2448. [10.1016/j.vaccine.2005.12.009]

Safety and immunogenicity of a combined DTPa-IPV vaccine administered as a booster from 4 years of age: a review.

FALDELLA, GIACOMO;
2006

Abstract

A combined DTPa-IPV booster vaccine was administered as a 4th or 5th dose after DTPa or DTPw priming. Over 99% vaccines developed antibody levels considered to be protective to diphtheria, tetanus and poliovirus, and >95% mounted a response to acellular pertussis antigens. Rectal temperature >39.5 degrees C was observed in at most 3.2% of vaccinees. Swelling >50 mm occurred in 24% of DTPa-primed compared to 5.5% of DTPw-primed children. Large swelling involving the entire upper arm (extending to involve the elbow joint) was reported for up to 1.2% of DTPa-primed subjects, which is consistent with literature reports for other DTPa vaccines.
2006
Safety and immunogenicity of a combined DTPa-IPV vaccine administered as a booster from 4 years of age: a review / Jacquet JM; Bégué P; Grimprel E; Reinert P; Sandbu S; Silfverdal SA; Faldella G; Nolan T; Lambert S; Richmond P; Marshall H; Roberton D; Schuerman L.. - In: VACCINE. - ISSN 0264-410X. - STAMPA. - 24(13):(2006), pp. 2440-2448. [10.1016/j.vaccine.2005.12.009]
Jacquet JM; Bégué P; Grimprel E; Reinert P; Sandbu S; Silfverdal SA; Faldella G; Nolan T; Lambert S; Richmond P; Marshall H; Roberton D; Schuerman L.
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/71316
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 26
  • ???jsp.display-item.citation.isi??? 21
social impact